Business Context and Reporting Period
Company: Vyome Holdings, Inc. (Ticker: HIND)
Filing Type: Form 10-Q (Unaudited)
Period: Quarter and nine months ended September 30, 2025
Key Event: The Company completed a reverse merger with Vyome Therapeutics, Inc. (VTI) on August 15, 2025. The transaction was accounted for as a reverse recapitalization with VTI as the accounting acquirer. The Company changed its name from Reshape Lifesciences, Inc. to Vyome Holdings, Inc. and began trading on the Nasdaq Capital Market.
Key Financial Metrics
| Metric | Nine Months Ended Sept 30, 2025 | Nine Months Ended Sept 30, 2024 | Three Months Ended Sept 30, 2025 |
|---|---|---|---|
| Revenue | $283,163 | $195,516 | $34,627 |
| Gross Profit | $196,705 | $132,209 | $18,050 |
| Operating Loss | $(9,097,496) | $(750,334) | $(8,574,310) |
| Net Loss | $(9,198,033) | $(1,140,904) | $(8,595,300) |
| Cash and Equivalents (Sept 30, 2025) | $5,707,012 | N/A | |
| Total Assets (Sept 30, 2025) | $7,045,396 | N/A | |
| Total Liabilities (Sept 30, 2025) | $3,126,936 | N/A |
Debt Status: All outstanding convertible notes and bridge notes were converted into common stock in connection with the Merger. As of September 30, 2025, there is no convertible debt outstanding.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 45% year-over-year for the nine-month period, driven by a $116,900 licensing milestone fee from the Luliconazole agreement with Sun Pharma. However, Q3 2025 revenue ($34,627) decreased 59% compared to Q3 2024 ($84,526) due to the termination of the dandruff product service fee arrangement in December 2024.
- Expense Surge: Operating expenses increased significantly to $9.29 million for the nine months ended Sept 30, 2025, compared to $0.88 million in the prior year. This was primarily driven by $7.7 million in transactional and financial advisory fees (including $5.9 million in stock-based compensation to advisors) related to the Merger.
- Liquidity Improvement: Cash and cash equivalents increased from $101,904 at December 31, 2024, to $5.71 million at September 30, 2025. This increase was funded by a private placement offering ($5.74 million), ATM sales ($0.68 million), and bridge notes ($0.60 million).
- Equity Structure: The Company executed a 1-for-5,000 reverse stock split. Total stockholders' equity turned positive ($3.92 million) from a deficit of $(4.39 million) at year-end 2024, largely due to capital raised and the conversion of debt to equity.
Guidance, Outlook, and Risks
- Outlook: Management believes current cash resources, combined with the ATM facility, are sufficient to fund operations for at least 15 months, including the initiation of the pivotal trial for lead candidate VT-1953. The Company plans to discuss the pivotal trial protocol with the FDA in the first half of 2026.
- Going Concern: While the Merger improved liquidity, the Company has a history of net losses and will require substantial additional funding to complete clinical trials and commercialize products. There is no assurance that future financing will be available on acceptable terms.
- Risks:
- Clinical Delays: Delays in regulatory approvals, patient recruitment, or manufacturing could increase costs and delay revenue generation.
- Customer Concentration: Substantially all revenue is derived from a single customer, Sun Pharma, in India.
- Capital Needs: Failure to raise additional capital could force the Company to delay trials, license assets to third parties, or cease operations.
- Unusual Items: The $7.7 million advisory fee expense is a non-recurring cost associated with the Merger transaction. Additionally, the Company recorded a favorable fair value adjustment of $30,511 on convertible debt in the nine-month period, compared to an unfavorable adjustment of $(239,686) in the prior year.
Investor Verification Checklist
- Merger Accounting: Verify the treatment of the reverse merger and the retroactive application of share counts (5,000:1 reverse split) in per-share calculations.
- Advisory Fees: Confirm the composition of the $7.7 million transactional fee, specifically the $5.9 million portion paid in stock to advisors and its impact on dilution.
- Revenue Sustainability: Assess the sustainability of revenue streams given the termination of the dandruff product agreement and reliance on the Luliconazole milestone/royalty model.
- Cash Runway: Validate the 15-month liquidity estimate against the burn rate, considering the high operating expenses incurred during the Merger period.
- Debt Conversion: Confirm that all convertible debt and bridge notes were fully converted to equity and that no hidden liabilities remain from the Reshape Lifesciences legacy.